Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 8:19 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #11 of 100 |
Slide #11. Actavis — Four Products from Akorn
Acquirer:
Actavis (NASDAQ:ACT)
Acquiree:
Four Products from Akorn
Details:
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed.
Enact Holdings is a private mortgage insurance company. Through its subsidiaries, Co. provides credit protection to mortgage lenders and investors, covering a portion of the unpaid principal balance of mortgage loans where the loan amount exceeds 80% of the value of the home ("low-down payment loans"). Co.'s credit protection provides families access to homeownership sooner than would otherwise be possible. Co. facilitates the sale of mortgages to the secondary market, including to the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation and private investors, and protect the balance sheets of mortgage lenders that retain mortgages in their portfolios.
ACT SEC Filing Email Alerts Service
Preferred: ACT.PRA
Open the ACT Page at The Online Investor »
|
||||||||||||||||||||||||
Open the ACT Page at The Online Investor (in a new window) »
 Free ACT Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Hold (2.50 out of 4) 2nd percentile
(ranked lower than approx. 98% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
